Live Smallpox Vaccine Revertant Control via Vero E6 Cell Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The challenge is to manufacture a live smallpox vaccine with a reduced content of revertant strains (MSP) that form medium-sized plaques, as their content increases with the number of passages, making it difficult to remove through conventional methods like limiting dilution or plaque isolation.
Innovation Solution
The process involves inoculating a mutant virus into animal cells, specifically RK-13 and Vero E6 cells, where the virus forms plaques in RK-13 cells but not in Vero E6 cells, allowing for the selection and pooling of cultures with reduced MSP content, thereby reducing the revertant strain in the vaccine.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If the vaccine is passaged multiple times in rabbit kidney cells to maintain viral proliferation, then the vaccine production efficiency is improved, but the revertant strain content increases making it difficult to remove
Solution Approach 1:
The patent introduces Vero E6 cells as an intermediary system to detect and select against revertant strains. By using this intermediate cell line as a filter between the rabbit kidney cell culture system and the final vaccine product, the process maintains high productivity while achieving precise control of revertant content through the selective absence of plaque formation in the intermediary system.
2Manufacturing precision
If conventional methods like limiting dilution or plaque isolation are used to remove revertants, then the revertant content is reduced, but the manufacturing complexity and time increase
Solution Approach 1:
The patent employs a self-service mechanism where the Vero E6 cell system automatically performs the selection function. The revertant strains self-identify themselves by their inability to form plaques in Vero E6 cells, eliminating the need for complex external intervention methods like limiting dilution or plaque isolation, thereby reducing manufacturing complexity while maintaining precision.
3Productivity
If the vaccine is passaged multiple times to increase viral titer, then the productivity is improved, but the revertant strains become more difficult to remove
Solution Approach 1:
The patent performs preliminary action by establishing the Vero E6 cell selection system before final vaccine production. This preliminary filtering step ensures that even after multiple passages that increase viral titer, the harmful revertant strains are pre-eliminated, allowing high productivity without accumulating harmful factors.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
A safer live smallpox vaccine, which contains a lowered content of revertants, is provided. A process for manufacturing a live smallpox vaccine which comprises steps of: inoculating a master seed solution of an attenuated vaccinia virus to an appropriate number of containers (1 to n wherein n is an integer) of rabbit kidney cells and incubating them; inoculating a portion of the cultured solution obtained from each container to RK-13 cells and to Vero E6 cells and incubating them to thereby select containers which contain a cultured solution that forms plaques in RK-13 cells but not in Vero E6 cells; and preparing a drug substance of vaccine using the aforementioned cultured solution (working seed solution), and a live smallpox vaccine prepared in the aforementioned process.